Acurx Pharmaceuticals Inc Stock Price, News & Analysis

Acurx Pharmaceuticals (NASDAQ: ACXP) announced its upcoming inclusion in the Russell Microcap Index effective September 20, 2021. This inclusion is based on market-capitalization rankings and style attributes, lasting for one year. The company aims to develop a new class of antibiotics, with its lead candidate, ibezapolstat, targeting C. difficile infections. CEO David P. Luci highlighted that this recognition enhances the company's visibility among investors and reflects progress in their drug development objectives.

Acurx Pharmaceuticals (NASDAQ: ACXP) announced that David P. Luci, President & CEO, will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, at 7:00 A.M. ET. This conference will take place from September 13-15, 2021. Investors can access the live presentation via a webcast link provided in the press release. Acurx focuses on developing novel antibiotics for challenging infections, targeting Gram-positive bacteria such as Clostridioides difficile and MRSA.

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) reported its second quarter 2021 results, highlighting significant developments in its antibiotic research. The company received a $500,000 grant from Health Holland for collaboration on DNA pol IIIC inhibitors and filed a provisional patent for ibezapolstat aimed at treating C. difficile Infection (CDI). Financially, Acurx showed a net loss of $4.0 million for the quarter, up from $0.9 million the previous year, with increased administrative expenses of $3.9 million. As of June 30, 2021, the cash balance stood at $17.1 million.

Acurx Pharmaceuticals, a clinical stage biopharmaceutical company focused on innovative antibiotics, will have its President & CEO, David P. Luci, present at the Emerging Growth Conference on August 18, 2021, at 11:15 a.m. Eastern Time. This interactive online event aims to engage current stockholders and the investment community, allowing for potential Q&A. The conference will be webcast live and archived for 30 days on the company's website. Acurx is developing antibiotics targeting hard-to-treat infections, including MRSA and VRE.

Acurx Pharmaceuticals (Nasdaq: ACXP) announced a $500,000 grant from Health Holland to support a collaborative research project with Leiden University Medical Center. This project aims to explore the structure of DNA polymerase C from multi-drug resistant bacteria, enhancing the development of new antibiotics. Acurx will begin a Phase 2b clinical trial for Clostridioides difficile Infection (CDI) in late 2021, following promising results from an earlier trial where 100% of patients achieved primary efficacy endpoints. The research may lead to innovative treatments for serious Gram-positive pathogens.

Acurx Pharmaceuticals (NASDAQ: ACXP) will release its Q2 2021 financial results on August 17, 2021, at 8:30 a.m. ET. A conference call will be hosted by President David P. Luci and CFO Robert G. Shawah to discuss these results and provide a business update. The company is developing ibezapolstat, a novel oral antibiotic for C. difficile infection, which has received FDA designations as a Qualified Infectious Disease Product and Fast Track designation. Acurx plans to enroll in a Phase 2b efficacy study by the end of 2021.

Acurx Pharmaceuticals (NASDAQ: ACXP) filed a provisional patent for ibezapolstat, targeting Clostridioides difficile Infection (CDI) and aiming to improve gut microbiome health. Following a successful Phase 2a trial with a 100% clinical cure rate, Acurx will initiate a Phase 2b trial later this year. The company's approach focuses on dual-action therapy, potentially enhancing patient outcomes and reducing recurrence rates. The announcement reflects Acurx's commitment to protecting its antimicrobial technologies.

Acurx Pharmaceuticals (Nasdaq ACXP) announced promising results for ibezapolstat in preventing Clostridioides difficile Infection (CDI) recurrence during the World Microbe Forum 2021. Utilizing specimens from a Phase 1 trial, analysis indicates ibezapolstat may lower CDI recurrence risk compared to vancomycin. Dr. Kevin Garey highlighted its unique microbiome impact, suggesting a restorative effect. Acurx plans to further validate these findings in a Phase 2b trial. CDI remains a serious health issue, with approximately 600,000 infections annually in the U.S.

Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) has successfully closed its initial public offering, selling 2,875,000 shares at $6.00 each, including an option for underwriters to purchase 375,000 additional shares. The offering generated approximately $14.8 million in net proceeds for the company. The SEC declared the registration statement effective on June 24, 2021. Acurx focuses on developing new antibiotics targeting difficult-to-treat bacterial infections.